SGBI — Sangui Biotech International Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for Sangui Biotech International, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2018 June 30th | 2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.077 | 0.088 | 0.029 | 0.066 | 0.069 |
| Cost of Revenue | |||||
| Gross Profit | 0.077 | 0.088 | 0.029 | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 0.285 | 0.426 | 0.217 | 0.217 | 0.213 |
| Operating Profit | -0.208 | -0.338 | -0.188 | -0.151 | -0.144 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -0.216 | -0.343 | -0.199 | -0.204 | -0.063 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -0.216 | -0.343 | -0.199 | -0.204 | -0.063 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -0.202 | -0.324 | -0.193 | -0.199 | -0.059 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -0.202 | -0.324 | -0.193 | -0.199 | -0.059 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.001 | -0.002 | -0.001 | -0.001 | -0 |